Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of SG301 SC in primary immune thrombocytopenia
CTR20261653Phase 2Active
- Sponsor
- Shangjian Bio
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SG301 in immune thrombocytopenia (ITP), sponsored by Shangjian Bio. Started Jun 2026; status: active.
02
Drugs
SG301
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20261653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261653.